JP2016536372A - クレアチン類似体及びその使用 - Google Patents

クレアチン類似体及びその使用 Download PDF

Info

Publication number
JP2016536372A
JP2016536372A JP2016553225A JP2016553225A JP2016536372A JP 2016536372 A JP2016536372 A JP 2016536372A JP 2016553225 A JP2016553225 A JP 2016553225A JP 2016553225 A JP2016553225 A JP 2016553225A JP 2016536372 A JP2016536372 A JP 2016536372A
Authority
JP
Japan
Prior art keywords
substituted
hydrogen
residue
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016553225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536372A5 (enrdf_load_stackoverflow
Inventor
スティーブン ジャングルス
スティーブン ジャングルス
ユーモ チャン
ユーモ チャン
エミル カッキス
エミル カッキス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ultragenyx Pharmaceutical Inc
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of JP2016536372A publication Critical patent/JP2016536372A/ja
Publication of JP2016536372A5 publication Critical patent/JP2016536372A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/08—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and more than one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62—Three oxygen atoms, e.g. ascorbic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Furan Compounds (AREA)
JP2016553225A 2013-11-05 2014-11-05 クレアチン類似体及びその使用 Pending JP2016536372A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899975P 2013-11-05 2013-11-05
US61/899,975 2013-11-05
PCT/US2014/064028 WO2015069699A1 (en) 2013-11-05 2014-11-05 Creatine analogs and the use thereof

Publications (2)

Publication Number Publication Date
JP2016536372A true JP2016536372A (ja) 2016-11-24
JP2016536372A5 JP2016536372A5 (enrdf_load_stackoverflow) 2017-10-19

Family

ID=53042015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016553225A Pending JP2016536372A (ja) 2013-11-05 2014-11-05 クレアチン類似体及びその使用

Country Status (6)

Country Link
US (1) US20160289175A1 (enrdf_load_stackoverflow)
EP (1) EP3065726A4 (enrdf_load_stackoverflow)
JP (1) JP2016536372A (enrdf_load_stackoverflow)
AU (1) AU2014346952A1 (enrdf_load_stackoverflow)
CA (1) CA2929538A1 (enrdf_load_stackoverflow)
WO (1) WO2015069699A1 (enrdf_load_stackoverflow)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021505537A (ja) * 2017-12-01 2021-02-18 ウルトラジェニクス ファーマシューティカル インク．Ｕｌｔｒａｇｅｎｙｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｃ． クレアチンプロドラッグ、組成物及びその使用方法
JP2023523033A (ja) * 2020-04-23 2023-06-01 カロサイト・インコーポレイテッド 自己組織化する酸素キャリアー組成物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9617230B2 (en) * 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
WO2016110822A1 (en) * 2015-01-09 2016-07-14 Universita' Degli Studi Di Genova Carboxylic biacyl creatine derivative, uses and method of synthesis thereof
TWI741979B (zh) 2015-03-30 2021-10-11 美商法明頓製藥發展公司 磷酸肌酸類似物前藥、其組成物及用途

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108596A1 (en) * 2001-08-23 2003-06-12 Sung Michael T. Lipophilic drug compositions
JP2004508407A (ja) * 2000-09-14 2004-03-18 ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ネブラスカ クレアチンエステル代替栄養素化合物及び調合物
JP2005528424A (ja) * 2002-06-04 2005-09-22 アビセナ グループ インコーポレイティッド 脳内エネルギー代謝を調節することによって認知機能障害を治療する方法
WO2007146086A1 (en) * 2006-06-06 2007-12-21 Xenoport, Inc. Creatine prodrugs, compositions and uses thereof
US7314945B1 (en) * 2007-02-20 2008-01-01 Multi Formulations Ltd. Creatine-fatty acids
US20080103202A1 (en) * 2004-11-08 2008-05-01 Chris Ferguson Method of preparing creatine ester salts and uses thereof.
WO2008101310A1 (en) * 2007-02-20 2008-08-28 Multi Formulations Ltd. Creatine-fatty acids
US20090297685A1 (en) * 2008-05-30 2009-12-03 Heuer Marvin A Preparations containing creatine and imino sugars
US20100215707A1 (en) * 2009-02-25 2010-08-26 Mcdonald Thomas Activated creatinine and precursors thereof as antibacterial agents, compositions and products containing such agents and uses thereof
US20110251280A1 (en) * 2010-04-08 2011-10-13 Owoc John H Stable Aqueous Compositions Comprising Amide-Protected Bioactive Creatine Species and Uses Thereof
US20110269986A1 (en) * 2008-12-24 2011-11-03 Sergej Vladimirovich Burov Amides of creatne, method of their preparation, and remedy possessing a neuroprotective activity
US20120065261A1 (en) * 2006-12-07 2012-03-15 Avicena Group, Inc. Creatine compositions for skin treatment
US20120277459A1 (en) * 2009-11-03 2012-11-01 Sergej Vladimirovich Burov Process for preparing creatine amides
WO2013043580A2 (en) * 2011-09-19 2013-03-28 Gencia Corporation Modified creatine compounds
JP2015526428A (ja) * 2012-07-30 2015-09-10 コミッサリア ア レネルジー アトミーク エ オ ゼネルジ ザルタナテイヴ クレアチン脂肪エステルを調製する方法、そのように調製されたクレアチン脂肪エステルおよびその使用

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508407A (ja) * 2000-09-14 2004-03-18 ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ネブラスカ クレアチンエステル代替栄養素化合物及び調合物
US20030108596A1 (en) * 2001-08-23 2003-06-12 Sung Michael T. Lipophilic drug compositions
JP2005528424A (ja) * 2002-06-04 2005-09-22 アビセナ グループ インコーポレイティッド 脳内エネルギー代謝を調節することによって認知機能障害を治療する方法
US20080103202A1 (en) * 2004-11-08 2008-05-01 Chris Ferguson Method of preparing creatine ester salts and uses thereof.
WO2007146086A1 (en) * 2006-06-06 2007-12-21 Xenoport, Inc. Creatine prodrugs, compositions and uses thereof
US20120065261A1 (en) * 2006-12-07 2012-03-15 Avicena Group, Inc. Creatine compositions for skin treatment
WO2008101310A1 (en) * 2007-02-20 2008-08-28 Multi Formulations Ltd. Creatine-fatty acids
US7314945B1 (en) * 2007-02-20 2008-01-01 Multi Formulations Ltd. Creatine-fatty acids
US20090297685A1 (en) * 2008-05-30 2009-12-03 Heuer Marvin A Preparations containing creatine and imino sugars
US20110269986A1 (en) * 2008-12-24 2011-11-03 Sergej Vladimirovich Burov Amides of creatne, method of their preparation, and remedy possessing a neuroprotective activity
US20100215707A1 (en) * 2009-02-25 2010-08-26 Mcdonald Thomas Activated creatinine and precursors thereof as antibacterial agents, compositions and products containing such agents and uses thereof
US20120277459A1 (en) * 2009-11-03 2012-11-01 Sergej Vladimirovich Burov Process for preparing creatine amides
US20110251280A1 (en) * 2010-04-08 2011-10-13 Owoc John H Stable Aqueous Compositions Comprising Amide-Protected Bioactive Creatine Species and Uses Thereof
WO2013043580A2 (en) * 2011-09-19 2013-03-28 Gencia Corporation Modified creatine compounds
JP2015526428A (ja) * 2012-07-30 2015-09-10 コミッサリア ア レネルジー アトミーク エ オ ゼネルジ ザルタナテイヴ クレアチン脂肪エステルを調製する方法、そのように調製されたクレアチン脂肪エステルおよびその使用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ADRIANO, E. ET AL.: "Searching for a therapy of creatine transporter deficiency: some effects of creatine ethyl ester in", NEUROSCIENCE (AMSTERDAM, NETHERLANDS), vol. 199, JPN6018025701, 2011, pages 386 - 393, XP028337137, ISSN: 0003976981, DOI: 10.1016/j.neuroscience.2011.09.018 *
BUROV, SERGEY ET AL.: "Creatinyl amino acids-new hybrid compounds with neuroprotective activity", JOURNAL OF PEPTIDE SCIENCE, vol. 17(9), JPN6018025698, 2011, pages 620 - 626, ISSN: 0003976978 *
FONS, C. ET AL.: "Response to creatine analogs in fibroblasts and patients with creatine transporter deficiency", MOLECULAR GENETICS AND METABOLISM, vol. 99(3), JPN6018025700, 2010, pages 296 - 299, ISSN: 0003976980 *
GARBATI, PATRIZIA ET AL.: "A new method to synthesize creatine derivatives", AMINO ACIDS, vol. 45(4), JPN6018025697, 2013, pages 821 - 833, ISSN: 0003976977 *
RU 2354645 C1, JPN7018002296, ISSN: 0003976983 *
SIMISTER, PHILIP C. ET AL.: "Novel inhibitors of a Grb2 SH3C domain interaction identified by a virtual screen", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 21(14), JPN6018025702, 2013, pages 4027 - 4033, ISSN: 0003976982 *
TROTIER-FAURION, ALEXANDRA ET AL.: "Synthesis and Biological Evaluation of New Creatine Fatty Esters Revealed Dodecyl Creatine Ester as", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56(12), JPN6018025699, 2013, pages 5173 - 5181, ISSN: 0003976979 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021505537A (ja) * 2017-12-01 2021-02-18 ウルトラジェニクス ファーマシューティカル インク．Ｕｌｔｒａｇｅｎｙｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｃ． クレアチンプロドラッグ、組成物及びその使用方法
JP2024009811A (ja) * 2017-12-01 2024-01-23 ウルトラジェニクス ファーマシューティカル インク． クレアチンプロドラッグ、組成物及びその使用方法
JP7433226B2 (ja) 2017-12-01 2024-02-19 ウルトラジェニクス ファーマシューティカル インク． クレアチンプロドラッグ、組成物及びその使用方法
JP7542705B2 (ja) 2017-12-01 2024-08-30 ウルトラジェニクス ファーマシューティカル インク． クレアチンプロドラッグ、組成物及びその使用方法
JP2023523033A (ja) * 2020-04-23 2023-06-01 カロサイト・インコーポレイテッド 自己組織化する酸素キャリアー組成物

Also Published As

Publication number Publication date
EP3065726A4 (en) 2017-06-21
EP3065726A1 (en) 2016-09-14
AU2014346952A1 (en) 2016-05-26
US20160289175A1 (en) 2016-10-06
WO2015069699A1 (en) 2015-05-14
CA2929538A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
US8202852B2 (en) Creatine phosphate analog prodrugs, compositions and uses thereof
JP7542705B2 (ja) クレアチンプロドラッグ、組成物及びその使用方法
US20070281995A1 (en) Creatine analog prodrugs, compositions and uses thereof
JP7676338B2 (ja) クレアチンプロドラッグ、その組成物、及びその使用方法
JP2016536372A (ja) クレアチン類似体及びその使用
US11021501B2 (en) Creatine phosphate analog prodrugs, compositions and methods of use thereof
US20070281910A1 (en) Salicyl alcohol creatine phosphate prodrugs, compositions and uses thereof
US20070281983A1 (en) Creatine analog prodrugs, compositions and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170904

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180705

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190214